Teva Pharmaceutical Industries Ltd. reported third-quarter 2026 revenue of $4.4 billion. Non-GAAP earnings per share were $0.86. Both results exceeded analyst forecasts.
Austedo, Ajovy and Uzedy collectively grew 33% year over year in local currency. Teva raised its 2026 revenue outlook for all three drugs.
Teva expanded its partnership with Samsung Bioepis to commercialize two biosimilars in the United States, strengthening its immunology portfolio. The company credited its Pivot to Growth strategy for its strong performance. It also significantly expanded its gross profit margin, and its credit rating rose to investment grade.